---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-286880"
form_type: "8-K"
ticker: "FDMT"
cik: "0001650648"
company_name: "4D Molecular Therapeutics, Inc."
filed_at: "2026-06-29T12:05:06+00:00"
generated_at: "2026-06-29T12:10:18.498926+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# 4D Molecular Therapeutics secures up to $200M term loan facility with Hercules Capital

## Summary
- Initial $20M drawn at closing; additional tranches available up to $200M total, maturing June 1, 2031.
- Interest rate: prime + 2.00% (min 8.75%) for Tranche 1A; other tranches prime + 2.50% (min 9.25%).
- Covenants include minimum cash test when borrowings exceed $25M or $50M; performance covenant tied to FDA approval and revenue.
- Loans secured by substantially all assets including intellectual property; future subsidiaries may guarantee obligations.

## SEC filing metadata
- accession: 0001193125-26-286880
- form_type: 8-K
- ticker: FDMT
- cik: 0001650648
- company_name: 4D Molecular Therapeutics, Inc.
- filed_at: 2026-06-29T12:05:06+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.03
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650648/000119312526286880/0001193125-26-286880-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650648/000119312526286880/d146057d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-286880
- JSON: https://secwatch.observer/filing/0001193125-26-286880.json
- Plain text: https://secwatch.observer/filing/0001193125-26-286880.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.